About Us

Advanced nanoparticle drug delivery systems

Our target-driven and cost-effective organization is committed to delivering advanced drug delivery platforms that offer added value to our partners and improve the quality of life of patients. Flexibility, compliance with the highest international quality standards and a true belief in the value of collaborative partnerships are the key elements of BioCyto’s approach. 

Our timeline

BioCyto Ltd was established in June 2017 after acquiring SmartCell Biologics cell nanoencapsulation, to apply its know-how to improving patient outcomes and access to optimal care by augmenting therapeutic efficacy.
In addition to creating a legacy portfolio of targeted drug delivery assists, BioCyto is focused on establishing co-development partnerships to commercialise applications of its platform technology.

2014
2015
2017
2019

2014

SmartCell Biologics was founded to develop novel cellular therapies based on bioencapsulation technology aimed at replacing the biological function of defective cells.

2015

Development of IP protected smart polymer microencapsulation material based on cellulose sulphates for use with vibrating nozzle technology.

2017

BioCyto incorporated – Acquired and adapted SmartCell Biologics know how to develop nanoparticle drug delivery platform, POC studies demonstrated the high commercial potential of the platform.

2019

NeuroDeliv patented – BioCyto’s first drug delivery platform developed to transpose the blood
brain barrier and control release therapeutics into the brain and successfully completes Series A funding round to develop and commercialise the technology.

What we do

BioCyto brings together decades of experience in the development and commercialisation of medical products. Leveraging domain expertise in neuroscience, drug delivery and commercialisation, we bring best practices and value to our customers.

We produce technologies that tackle major issues faced in targeted therapeutic delivery. Using our technologies, we provide significant advancements in therapeutic efficacy and patent safety.

Our aim is to support our partners throughout the research and development, manufacturing and quality control process. We will help to develop the next market leading therapeutics. 

We conduct our R&D activities out of the state of the art facilities at Trinity Biomedical Science Institute.